Abstracts tagged "Questionnaires"

Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Cristina Arriens¹, Dylan Forciea ², Judith James ¹ and Joan T. Merrill ³, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oseberg, Oklahoma City, OK, ³Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…
Abstract Number: 2272 • 2019 ACR/ARP Annual Meeting
Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies
Kristofer Andreasson¹, Helene Alexanderson ¹ and Heléne Sandlund ², ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The adult idiopathic inflammatory myopathies (IIM) comprise dermatomyositis (DM), necrotizing myopathy (NM), antisynthetase syndrome (ASS), overlap myositis and inclusion body myositis (IBM). Impaired muscle…
Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting
Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Brittany Adler¹, James Russell², Laura K. Hummers³ and Zsuzsanna McMahan⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Department of Internal Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
Abstract Number: 2466 • 2016 ACR/ARHP Annual Meeting
Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
Isabel Castrejón¹, Martin J. Bergman², Kathryn Gibson^3,4, Yusuf Yazici⁵, Joel Block⁶ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Taylor Hospital, Ridley Park, PA, ³Liverpool Hospital, Sydney, Sydney, Australia, ⁴Ingham Research Institute, Liverpool, Australia, ⁵Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Remission rates in patients with rheumatoid arthritis (RA) according to RAPID3 (routine assessment of patient index data) are reported at 25% in France1 and…
Abstract Number: 2519 • 2016 ACR/ARHP Annual Meeting
Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Mediola Ismajli¹ and Maria J. Leandro², ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Title: Predictors of flare in rheumatoid arthritis patients treated preventively with rituximab: a prospective study using ultrasound and patient reported outcomes Background/Purpose: Rituximab (RTX) is…
Abstract Number: 2895 • 2016 ACR/ARHP Annual Meeting
Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish
Murat Yasar Tas¹, Gozde Dervis Hakim², Pembe Keskinoglu³, Gokce Kenar⁴, Handan Yarkan⁵, Berrin Zengin⁴, Gerçek Can⁵, Fatos Onen⁴, Nurullah Akkoc⁴, Mesut Akarsu⁶ and Merih Birlik⁴, ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Gastroenterology, Ataturk State Hospital, Sinop, Turkey, ³Department of Biostatistics and Medical Informatics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁶Gastroenterology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Nearly 90% of patients with scleroderma (SSc) have gastrointestinal tract(GIT) involvement in variable severities and is a challenging process for clinicians.The University of California…
Abstract Number: 2713 • 2014 ACR/ARHP Annual Meeting
The Relationship of Patient Reported Skin Symptoms to the Scleroderma HAQ, the Modified Rodnan Skin Score and Skin Pathology.
Jessica Ziemek¹, Ada Man², Robert W. Simms² and Robert Lafyatis², ¹Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Changes in skin are a cardinal feature of systemic sclerosis (SSc). However, there are no SSc specific patient reported outcome measures validated for use…
Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Jessica Meijs¹, Daisy Pors¹, Theodora P.M. Vliet Vlieland², Tom W.J. Huizinga¹ and Annemie J.M. Schuerwegh¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…
Abstract Number: 1563 • 2012 ACR/ARHP Annual Meeting
Is Automated DATA Capture As Reliable As Manual DATA Entry in Survey Based Research?
Rachel A. Mikolaitis¹, Jessica Cornejo², Chris Alonzo¹, Joel A. Block¹ and Meenakshi Jolly², ¹Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: The collection of patient reported outcomes requires accruing survey data from patients during routine medical visits. Many of these are paper-based and require manual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].